CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

Clinical trial NCT06262438 · RECRUITING

Trial details

NCT number: NCT06262438
Sponsor: Princess Maxima Center for Pediatric Oncology
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia in Children

Start date: 2024-02-06
Primary completion: 2028-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.